A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC).

被引：1
|
作者：
Tew, William P.
Sill, Michael
McMeekin, D. Scott
Secord, Angeles Alvarez
Bonebrake, Albert J.
Schilder, Jeanne
Stuckey, Ashley
Rice, Laurel
Tewari, Krishnansu Sujata
Aghajanian, Carol
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Gynecol Oncol Grp Stat & Data Ctr, Buffalo, NY USA
[3] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA
[4] Duke Univ, Med Ctr, Durham, NC USA
[5] Canc Res Ozarks Cox Hlth, Springfield, MO USA
[6] Indiana Univ, Indianapolis, IN 46204 USA
[7] Brown Univ, Women & Infants Hosp, Providence, RI USA
[8] Univ Wisconsin, Madison, WI USA
[9] Univ Calif Irvine, Med Ctr, Orange, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.5546
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5546
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II trial of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Hagemann, Andrea R.
    Zighelboim, Israel
    Novetsky, Akiva Pesach
    Gao, Feng
    Massad, L. Stewart
    Thaker, Premal H.
    Powell, Matthew A.
    Mutch, David Gardner
    Wright, Jason D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study
    Tew, William P.
    Sill, Michael W.
    Walker, Joan L.
    Secord, Angeles Alvarez
    Bonebrake, Albert J.
    Schilder, Jeanne M.
    Stuckey, Ashley
    Rice, Laurel
    Tewari, Krishnansu S.
    Aghajanian, Carol A.
    GYNECOLOGIC ONCOLOGY, 2018, 151 (02) : 257 - 263
  • [3] Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer
    Hagemann, Andrea R.
    Novetsky, Akiva P.
    Zighelboim, Israel
    Gao, Feng
    Massad, L. Stewart
    Thaker, Premal H.
    Powell, Matthew A.
    Mutch, David G.
    Wright, Jason D.
    GYNECOLOGIC ONCOLOGY, 2013, 131 (03) : 535 - 540
  • [4] Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer
    Taylor, Sarah E.
    Chu, Tianjiao
    Elvin, Julia A.
    Edwards, Robert P.
    Zorn, Kristin K.
    GYNECOLOGIC ONCOLOGY, 2020, 156 (01) : 32 - 37
  • [5] Phase II study of everolimus (EV) and bevacizumab (BEV) in recurrent ovarian, peritoneal, and fallopian tube cancer.
    Taylor, Sarah E.
    Chu, Tianjiao
    Edwards, Robert P.
    Zorn, Kristin Kelley
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study
    Burger, R. A.
    Brady, M. F.
    Bookman, M. A.
    Walker, J. L.
    Homesley, H. D.
    Fowler, J.
    Monk, B. J.
    Greer, B. E.
    Boente, M.
    Liang, S. X.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [7] Oral cyclophosphamide plus bevacizumab in recurrent ovarian, fallopian tube and primary peritoneal cancer
    Eyada, Mostafa
    Michael, Victoria
    Fellman, Bryan M.
    Patel, Shrina
    Soliman, Pamela T.
    How, Jeffrey Andrew
    Jazaeri, Amir A.
    Fleming, Nicole D.
    Sood, Anil K.
    Westin, Shannon Neville
    Sims, Travis T.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study.
    Burger, RA
    Sill, M
    Monk, BJ
    Greer, B
    Sorosky, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 457S - 457S
  • [9] A phase II trial of pembrolizumab in combinationwith bevacizumab and oral metronomic cyclophosphamide for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer
    Zsiros, E.
    Frederick, P. J.
    Akers, S. N.
    Attwood, K.
    Wang, K.
    Lele, S. B.
    Odunsi, K.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 23 - 23
  • [10] ICON7: A PHASE III RANDOMISED GYNAECOLOGIC CANCER INTERGROUP TRIAL OF CONCURRENT BEVACIZUMAB AND CHEMOTHERAPY FOLLOWED BY MAINTENANCE BEVACIZUMAB, VERSUS CHEMOTHERAPY ALONE IN WOMEN WITH NEWLY DIAGNOSED EPITHELIAL OVARIAN (EOC), PRIMARY PERITONEAL (PPC) OR FALLOPIAN TUBE CANCER (FTC)
    Perren, T.
    Swart, A. M.
    Pfisterer, J.
    Ledermann, J.
    Lortholary, A.
    Kristensen, G.
    Carey, M.
    Beale, P.
    Cervantes, A.
    Oza, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 2 - 3
12345